Clinical trial · Interventional
Oral Cancer Screening for Early Detection of Premalignant Disorders (PMOD)
Screening for Oral Cancer for Early Detection of Premalignant Disorders
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer is a complex disease; its different causes and types have a strong impact on patient treatment and prognosis. To improve understanding of the disease, its causes and progression, the investigators will develop a simple, cost-effective system for continuous control of mucosal lesions with non-invasive brush biopsy that can be managed in primary dental care, as an alternative to tissue biopsy in order to reduce the number of oral cavity cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mouth Neoplasms | Oral Cavity Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brush sampling | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Brush biopsy
- description
- Brusch biopsy at baseline and at 3 or 6 months
- interventionNames
- Procedure: Brush sampling
- type
- ACTIVE_COMPARATOR
- label
- Care as usual
- description
- Control at 3 or 6 month, surgical biopsy when needed
- interventionNames
- Procedure: Brush sampling
Primary outcomes (1)
- measure
- Numbers of cancers diagnosed by brush sampling
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: • Persons 18 years of age or older who have the clinical diagnosis of leukoplakia, erythroplakia or proliferative verrukös leukoplakia Exclusion Criteria: * People who cannot read and understand information in Swedish. * Ongoing chemotherapy and/or radiotherapy.
References
Publications (0)
Data not yet available